This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Segura, C.
Right arrow Articles by Coira, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segura, C.
Right arrow Articles by Coira, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1524-1526, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Contribution of beta -Lactamases to beta -Lactam Susceptibilities of Susceptible and Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates

C. Segura,1,2,* M. Salvadó,1,2 I. Collado,3 J. Chaves,3 and A. Coira3

Laboratori de Referència de Catalunya1 and Departament de Genética y Microbiología,2 Universitat Autònoma de Barcelona, and Institut Municipal d'Investigació Mèdica,3 Barcelona, Spain

Received 4 September 1997/Returned for modification 18 December 1997/Accepted 24 March 1998

    ABSTRACT
Top
Abstract
Text
References

The beta -lactamases in 154 clinical Mycobacterium tuberculosis strains were studied. Susceptibilities to beta -lactam antibiotics, their combination with clavulanate (2:1), and two fluoroquinolones were determined in 24 M. tuberculosis strains susceptible to antimycobacterial drugs and in nine multiresistant strains. All 154 M. tuberculosis isolates showed a single chromosomal beta -lactamase pattern (pI 4.9 and 5.1). M. tuberculosis beta -lactamase hydrolyzes cefotaxime with a maximum rate of 22.5 ± 2.19 IU/liter (strain 1382). Neither amoxicillin, carbenicillin, cefotaxime, ceftriaxone, nor aztreonam was active alone. Except for aztreonam, beta -lactam combinations with clavulanate produced better antimycobacterial activity.

    TEXT
Top
Abstract
Text
References

The rise in the incidence of tuberculosis and the increasing resistance to antimycobacterial drugs (2, 3), particularly in human immunodeficiency virus-infected patients, underline the urgent need for new compounds which overcome this resistance. Reevaluation of old compounds, such as the beta -lactam group, a widely used, nontoxic and extensively developed group, could be one way to address this problem.

Mycobacterium tuberculosis has been historically considered intrinsically resistant to beta -lactam antibiotics, owing to its beta -lactamase and impermeability. Reports of susceptibility to this group of antibiotics and the role of beta -lactamase in resistance are documented; however, they are scarce and do not study the beta -lactam activity in multidrug-resistant strains (7-10, 21). Systematic study of M. tuberculosis beta -lactamases and their correlation with beta -lactam and inhibitor susceptibility data could be interesting in the search for effective compounds.

We studied beta -lactamases in 154 M. tuberculosis individual nonreplicate strains isolated from clinical specimens between 1991 and 1993 at the Laboratori de Referència de Catalunya. Susceptibility tests were performed on 22 of these strains. Furthermore, 11 strains (8 multidrug resistant) from Trías i Pujol University Hospital of Badalona were included in the susceptibility assays.

Standard biochemical tests and nucleic acid hybridization tests (Accuprobe; Gen-Probe Inc., San Diego, Calif.) were employed for the identification of clinical isolates (12, 13, 23).

beta -Lactamase characterization. The qualitative spectrum of hydrolysis of the beta -lactamases was screened by using an acidimetric method (20). Determination of the isoelectric point was carried out in crude extracts by analytical isoelectric focusing (17) with commercially prepared polyacrylamide gel plates (pH 3.5 to 9.5 and 4.0 to 6.5) and LKB instrumentation. Crude extracts were obtained by ultrasonication in an ice bath (Branson 2000 sonicator for 60 min) of a 9-McFarland (27 × 108 bacteria/ml) bacterial suspension in distilled water. Cell debris was removed by centrifugation (Ultracentrifuge TL100; Beckman Instruments Inc.) at 20,000 rpm and 4°C for 20 min. The beta -lactamase activity of extracts was determined with a 50-µg/ml nitrocefin solution. Hydrolysis of nitrocefin and cefotaxime was determined spectrophotometrically for a crude extract obtained from the susceptible strain 1382 (4). Wavelengths selected were 495 nm for nitrocefin and 264 nm for cefotaxime (Shimadzu UV-160 spectrophotometer). Various concentrations of antibiotics in 0.1 M sodium phosphate buffer (pH 7) were tested with 0.1 ml of crude extract (total volume, 1.6 ml). The varepsilon  value used for these calculations was that reported by Amicosante et al. (1). Km values and maximum rates (Vmax) were obtained according to Michaelis-Menten plots by using the Fig P program (Fig. P Software Corp., Durham, N.C.). Enzymatic activity is reported in international units/liter of crude extract, where an international unit is defined as the amount of enzyme hydrolyzing 1 µmol of substrate per min.

Susceptibility tests. MICs were determined by agar dilution with 7H10 agar supplemented with 10% oleic acid-albumin-dextrose-catalase. Mycobacteria were grown in 7H9 broth at 37°C and diluted with distilled water to match the turbidity of a 1-McFarland standard (approximately 2 × 108 CFU/ml) (7). The plates were inoculated by using a Steer's replicator with a 1/100 dilution in distilled water of the above suspension. The results were read after 3 weeks of incubation in a CO2 atmosphere at 37°C. The MIC was defined as the lowest concentration of antibiotic which completely inhibited visible bacterial growth (one colony was disregarded). M. tuberculosis H37Rv (ATCC 25618), Staphylococcus aureus ATCC 25923, and Escherichia coli ATCC 25922 were used as controls. The antibiotics evaluated, kindly provided as standard powders by the manufacturers, were lithium clavulanate, amoxicillin, carbenicillin, cefotaxime, ceftriaxone, aztreonam, rifampin, isoniazid, streptomycin, ciprofloxacin, and ofloxacin. Combinations with clavulanate were made at a 2/1 ratio (beta -lactam/inhibitor ratio). The stabilities of the antibiotics during the incubation period were monitored by inoculation of the plates with the E. coli control strain (ATCC 25922) on days 1 and 11.

The 154 strains and the type strain H37Rv expressed beta -lactamases which hydrolyzed benzylpenicillin and cephaloridine in the qualitative acidimetric assay, and all strains showed the same pattern of beta -lactamase bands by analytical isoelectric focusing, with two major bands with isoelectric points (pIs) of 4.9 and 5.1.

The susceptibility data are presented in two groups according to the results of the antimycobacterial agents tested. Multidrug resistance was reported when resistance was observed for at least two drugs (Table 1).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   MICs of antimycobacterial agents for susceptible and multidrug-resistant M. tuberculosis isolates

The fluoroquinolones, rifampin, streptomycin, and all the beta -lactam antibiotics except carbenicillin and its combination with clavulanate appeared to be stable during the extended incubation period. MICs of the agents tested against E. coli (ATCC 25922) on days 1 and 11 were the same. Carbenicillin and its combination with clavulanate were the only antibiotics for which some degradation was observed; that is, the MIC on day 11 was 2 dilutions higher than that on day 1. As seen in Table 2, neither amoxicillin, carbenicillin, cefotaxime, ceftriaxone, nor aztreonam was active against the M. tuberculosis strains studied. For all of them except aztreonam, the combination with the beta -lactamase inhibitor produced better antimycobacterial activity.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   MICs of several beta -lactam antibiotics alone and in combination with clavulanate (2:1 ratio) and two fluoroquinolones

Nitrocefin hydrolysis was used to verify the enzymatic activity of the extract. With nitrocefin as the substrate, a Km of 68 ± 12 µM and a Vmax of 10.61 ± 0.59 IU/liter were calculated. For cefotaxime, Vmax was 22.5 ± 2.19 IU/liter and Km was 0.46 ± 0.16 µM at the concentration ranges assayed (between 0.33 and 5 µM); when higher concentrations were employed no activity was detected, suggesting substrate inhibition like those of other beta -lactamases (5, 22).

The 154 M. tuberculosis clinical isolates and the control strain studied showed only one pattern of chromosomal beta -lactamase with two major bands, with pIs of 4.9 and 5.1, the same pattern recorded by other authors (16, 24, 25). These results agree with other genetic and phenotypic studies showing minimal heterogeneity in M. tuberculosis (11, 15, 19).

Chromosomal beta -lactamase is the main resistance determinant observed for amoxicillin, carbenicillin, ceftriaxone, and cefotaxime. This can be deduced from the comparison of the MIC results for these compounds alone and their combination with clavulanate and is reinforced by cefotaxime hydrolysis results. Clavulanate has no antibacterial activity in M. tuberculosis due to the lack of affinity for penicillin-binding proteins (PBPs) (9), but it is a powerful inhibitor of its beta -lactamase (21, 25). The results observed were not simply due to an additive effect unrelated to beta -lactamase inhibition, since beta -lactams tested bound to M. tuberculosis PBPs at therapeutically achievable concentrations (9), and they are also reinforced by the fact that clavulanate did not reduce aztreonam MICs at the concentrations assayed. These results concur with those reported previously for some beta -lactams, although some were obtained by another MIC determination method (7-10, 21).

M. tuberculosis beta -lactamase belongs to the class A beta -lactamases (14); its resistance phenotype, qualitative hydrolysis spectrum, cefotaxime hydrolysis, and clavulanate inhibition indicate that M. tuberculosis beta -lactamase could be a group 2be beta -lactamase according to the classification of Bush et al. (6). Although Hackbarth et al. (14) also described the presence, in the H37Ra strain, of the bla C (beta -lactamase class C gene), not in close proximity to bla A, it is not clear if the class C beta -lactamase is produced by M. tuberculosis.

beta -Lactam antibiotics could be considered for the treatment of tuberculosis caused by multidrug-resistant strains. Chambers et al. (9) evaluated positively not only the factors that determine the susceptibility of M. tuberculosis strains to beta -lactam antibiotics (PBPs and permeability) but also the macrophage penetration. Furthermore, the amoxicillin-clavulanate combination has been successfully used to treat patients with multidrug-resistant tuberculosis when the combination was administered with second-line drugs (18).

MICs of the two fluoroquinolones assayed and of all the beta -lactams except the amoxicillin-clavulanate combination were very similar in the two groups of strains studied (antimycobacterial drug susceptible and multidrug resistant). In order to determine the future role of beta -lactams in the treatment of tuberculosis, it will be necessary to study additional strains and to evaluate the activities of beta -lactams in combination with other antimycobacterial drugs in vitro and in an animal model.

    ACKNOWLEDGMENTS

This research was supported by a grant from the FIS (Fondo de Investigaciones Sanitarias de la Seguridad Social) (93/0490).

We gratefully acknowledge Xavier Remesar (Departamento de Bioquímica y Biología Molecular, Universidad de Barcelona) for his valuable assistance in the enzymatic analysis.

    FOOTNOTES

* Corresponding author. Mailing address: Cerdeña 257, 3o 1a, Barcelona 08013, Spain. Phone: (34)-3-2630920. Fax: (34)-3-2630671. E-mail: msalvador{at}lrc.es.

    REFERENCES
Top
Abstract
Text
References

1. Amicosante, G., N. Franceschini, B. Segatore, A. Oratore, et al. 1990. Characterization of a betalactamase produced in Mycobacterium fortuitum D316. Biochem. J. 271:729-734[Medline].
2. Bloom, B. R., and C. J. C. Murray. 1992. Tuberculosis: commentary on a reemergent killer. Science 257:1055-1064[Abstract/Free Full Text].
3. Brudney, K., and J. Dobkin. 1992. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am. Rev. Respir. Dis. 144:745-749.
4. Bush, K., and R. B. Sykes. 1984. Beta-lactamase (penicillinase, cephalosporinase), p. 280-284. In H. U. Bergmeyer (ed.), Methods of enzymatic analysis, 3rd ed., vol. 4. Verlag Chemie, Weinheim, Germany.
5. Bush, K., and R. B. Sykes. 1986. Methodology for the study of beta -lactamases. Antimicrob. Agents Chemother. 30:6-10[Free Full Text].
6. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta -lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233[Medline].
7. Casal, M., F. Rodríguez, and M. Benavente. 1986. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to amoxicillin/clavulanic acid. Eur. J. Clin. Microbiol. 5:453-454[Medline].
8. Casal, M. J., F. C. Rodriguez, M. D. Luna, and M. C. Benavente. 1987. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid. Antimicrob. Agents Chemother. 31:132-133[Abstract/Free Full Text].
9. Chambers, H. F., D. Moreau, D. Yajko, C. Miick, C. Wagner, C. Hackbarth, S. Kocagöz, E. Rosenberg, W. K. Hadley, and H. Nikaido. 1995. Can penicillins and other beta -lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39:2620-2624[Abstract].
10. Cynamon, M. H., and G. S. Palmer. 1983. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 24:429-431[Abstract/Free Full Text].
11. Eisenach, K. D., J. T. Crawford, and J. H. Bates. 1986. Genetic relatedness among strains of Mycobacterium tuberculosis complex. Am. Rev. Respir. Dis. 133:1065-1068[Medline].
12. Ellner, P. D., T. E. Kiehn, R. Camarata, and M. Hosmer. 1988. Rapid detection and identification of pathogenic mycobacteria by combining radiometric and nucleic acid probe methods. J. Clin. Microbiol. 23:1349-1352.
13. Evans, K. D., A. S. Nakasone, P. A. Sutherland, L. M. de la Maza, and E. M. Peterson. 1992. Identification of Mycobacterium tuberculosis and Mycobacterium avium-M. intracellulare directly from primary BACTEC cultures by using acridinum-ester-labeled DNA probes. J. Clin. Microbiol. 30:2427-2431[Abstract/Free Full Text].
14. Hackbarth, C. J., I. Unsal, and H. F. Chambers. 1997. Cloning and sequence analysis of a class A beta -lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 41:1182-1185[Abstract].
15. Jones, W. D., R. C. Good, N. J. Thompson, and G. D. Kely. 1982. Bacteriophage types of Mycobacterium tuberculosis in the United States. Am. Rev. Respir. Dis. 125:640-643[Medline].
16. Kwon, H. H., H. Tomioka, and H. Saito. 1995. Distribution and characterization of betalactamases of mycobacteria and related organisms. Tubercle Lung Dis. 76:141-148[Medline].
17. Matthew, M., A. M. Harris, M. J. Marshall, and G. W. Ross. 1975. The use of analytical isoelectric focusing for detection and identification of betalactamases. J. Gen. Microbiol. 88:169-178[Medline].
18. Nadler, J. P., J. Berger, J. A. Nord, R. Cofsky, and M. Saxena. 1991. Amoxicillin clavulanic acid for treating drug resistant Mycobacterium tuberculosis. Chest 99:1025-1026[Abstract/Free Full Text].
19. Román, M. C., and L. M. J. Sicilia. 1984. Preliminary investigation of Mycobacterium tuberculosis biovars. J. Clin. Microbiol. 20:1015-1016[Abstract/Free Full Text].
20. Roy, C., C. Segura, M. Tirado, and R. Reig. 1984. Determinación orientativa del espectro de hidrólisis de las betalactamasas de enterobacteriáceas y de Pseudomonas aeruginosa. Rev. Diagn. Biol. 33:27-32.
21. Sorg, T. B., and M. H. Cynamon. 1987. Comparison of four betalactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 19:59-64[Abstract/Free Full Text].
22. Vu, H., and H. Nikaido. 1985. Role of beta -lactam hydrolysis in the mechanism of resistance of a beta -lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta -lactams. Antimicrob. Agents Chemother. 27:393-398[Abstract/Free Full Text].
23. Wayne, L. G., and G. P. Kubica. 1986. Family Mycobacteriaceae, p. 1436-1457. In P. H. A. Sneath, N. S. Mair, M. E. Sharpe, and J. G. Holt (ed.), Bergey's manual of systematic bacteriology, vol. 2. Williams and Wilkins, Baltimore, Md.
24. Wong, C., M. Cynamon, and J. Gavalchin. 1989. Characterization of the beta -lactamase of Mycobacterium tuberculosis, abstr. U-85, p. 169. In Abstracts of the 89th Annual Meeting of the American Society for Microbiology 1989. American Society for Microbiology, Washington, D.C.
25. Zhang, Y., V. Steingrube, and R. J. Wallace. 1992. Betalactamase inhibitors and the inducibility of the betalactamase of Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 145:657-660[Medline].

Antimicrobial Agents and Chemotherapy, June 1998, p. 1524-1526, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hugonnet, J.-E., Tremblay, L. W., Boshoff, H. I., Barry, C. E. 3rd, Blanchard, J. S. (2009). Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis. Science 323: 1215-1218 [Abstract] [Full Text]  
  • Wang, F., Cassidy, C., Sacchettini, J. C. (2006). Crystal Structure and Activity Studies of the Mycobacterium tuberculosis {beta}-Lactamase Reveal Its Critical Role in Resistance to {beta}-Lactam Antibiotics.. Antimicrob. Agents Chemother. 50: 2762-2771 [Abstract] [Full Text]  
  • Flores, A. R., Parsons, L. M., Pavelka,, M. S. Jr (2005). Genetic analysis of the {beta}-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to {beta}-lactam antibiotics. Microbiology 151: 521-532 [Abstract] [Full Text]  
  • Philalay, J. S., Palermo, C. O., Hauge, K. A., Rustad, T. R., Cangelosi, G. A. (2004). Genes Required for Intrinsic Multidrug Resistance in Mycobacterium avium. Antimicrob. Agents Chemother. 48: 3412-3418 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Segura, C.
Right arrow Articles by Coira, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segura, C.
Right arrow Articles by Coira, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»